Capturing the catalytic intermediates of parkin ubiquitination.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
06 Aug 2024
Historique:
medline: 30 7 2024
pubmed: 30 7 2024
entrez: 30 7 2024
Statut: ppublish

Résumé

Parkin is an E3 ubiquitin ligase implicated in early-onset forms of Parkinson's disease. It catalyzes a transthiolation reaction by accepting ubiquitin (Ub) from an E2 conjugating enzyme, forming a short-lived thioester intermediate, and transfers Ub to mitochondrial membrane substrates to signal mitophagy. A major impediment to the development of Parkinsonism therapeutics is the lack of structural and mechanistic detail for the essential, short-lived transthiolation intermediate. It is not known how Ub is recognized by the catalytic Rcat domain in parkin that enables Ub transfer from an E2~Ub conjugate to the catalytic site and the structure of the transthiolation complex is undetermined. Here, we capture the catalytic intermediate for the Rcat domain of parkin in complex with ubiquitin (Rcat-Ub) and determine its structure using NMR-based chemical shift perturbation experiments. We show that a previously unidentified α-helical region near the Rcat domain is unmasked as a recognition motif for Ub and guides the C-terminus of Ub toward the parkin catalytic site. Further, we apply a combination of guided AlphaFold modeling, chemical cross-linking, and single turnover assays to establish and validate a model of full-length parkin in complex with UbcH7, its donor Ub, and phosphoubiquitin, trapped in the process of transthiolation. Identification of this catalytic intermediate and orientation of Ub with respect to the Rcat domain provides important structural insights into Ub transfer by this E3 ligase and explains how the previously enigmatic Parkinson's pathogenic mutation T415N alters parkin activity.

Identifiants

pubmed: 39078678
doi: 10.1073/pnas.2403114121
doi:

Substances chimiques

Ubiquitin-Protein Ligases EC 2.3.2.27
parkin protein EC 2.3.2.27
Ubiquitin 0
Ubiquitin-Conjugating Enzymes EC 2.3.2.23

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2403114121

Subventions

Organisme : Canadian Government | Canadian Institutes of Health Research (CIHR)
ID : PJT14606
Organisme : Wellcome Trust (WT)
ID : 209347/Z/17/Z

Déclaration de conflit d'intérêts

Competing interests statement:The authors declare no competing interest.

Auteurs

Elizabeth M Connelly (EM)

Department of Biochemistry, The University of Western Ontario, London, ON N6A 5C1, Canada.

Anne C Rintala-Dempsey (AC)

Department of Biochemistry, The University of Western Ontario, London, ON N6A 5C1, Canada.

Mehmet Gundogdu (M)

School of Molecular Biosciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK.

E Aisha Freeman (EA)

Department of Biochemistry, The University of Western Ontario, London, ON N6A 5C1, Canada.

Joanna Koszela (J)

School of Molecular Biosciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK.

Jacob D Aguirre (JD)

Department of Biochemistry, The University of Western Ontario, London, ON N6A 5C1, Canada.

Grace Zhu (G)

Department of Biochemistry, The University of Western Ontario, London, ON N6A 5C1, Canada.

Outi Kämäräinen (O)

School of Molecular Biosciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK.

Roya Tadayon (R)

Department of Biochemistry, The University of Western Ontario, London, ON N6A 5C1, Canada.

Helen Walden (H)

School of Molecular Biosciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK.

Gary S Shaw (GS)

Department of Biochemistry, The University of Western Ontario, London, ON N6A 5C1, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH